GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

NanoRepro NN6.DE · EUR

Health Care · XETRA · 🇩🇪 Germany

Compare

1.58

+0.64%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2025

Revenue

€4.7m

FY2016FY2025

Net income

−€2.0m

FY2016FY2025

Free cash flow

—

FY2016FY2025

Shareholders' equity

€36.2m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue€4.7m€4.6m€3.2m€38.5m€162.7m€16.9m€1.2m€2.7m€2.0m€1.9m
Operating income€1.2m−€3.6m−€5.3m−€4.5m€38.8m€2.8m−€1.2m−€323,449−€723,576−€1.1m
Net income−€2.0m−€2.0m−€4.7m−€3.7m€29.7m€1.7m−€1.2m−€289,619−€734,075−€551,675
Diluted earnings per share-0.16-0.16-0.37-0.292.300.18-0.14-0.03-0.10-0.08

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets€36.8m€39.0m€41.5m€49.5m€79.1m€11.2m€4.8m€5.8m€4.2m€3.5m
Cash and short-term investments€7.8m€9.1m€20.6m€31.3m€28.0m€1.2m€737,152€1.8m€528,051€530,122
Total liabilities€678,458€884,033€1.1m€2.0m€21.5m€3.2m€374,210€188,116€373,312€478,776
Debt———€1€150,000€1.4m€198,177€238€135,873€155,975
Shareholders' equity€36.2m€38.1m€40.4m€47.4m€57.6m€8.0m€4.4m€5.6m€3.8m€3.0m
Shares outstanding13m13m13m13m13m9m9m8m7m7m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations—€9.9m−€10.3m€13.1m€8.2m−€1.1m−€612,400−€257,600−€1.1m−€769,699
Capital spending—−€402,600—−€3.3m−€1,400−€500−€618,000−€441,300−€3,800−€800
Free cash flow—€9.5m−€10.3m€9.8m€8.2m−€1.1m−€1.2m−€698,900−€1.1m−€770,499
Dividends paid——−€1.9m−€6.5m——————

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023Dec 2022
Revenue€1.9m€2.4m€2.7m€1.8m€1.8m€1.4m€696,000€12.5m
Operating income−€1.3m−€939,777−€1.4m−€2.3m−€2.6m−€2.7m−€1.3m−€7.0m
Net income−€1.1m−€843,695−€880,332−€1.2m−€2.0m−€2.7m−€1.3m−€3.9m
Diluted earnings per share-0.09-0.07-0.07-0.09-0.16-0.21-0.10-0.30
Cash from operations—€2.0m—€9.0m−€10.0m——€8.0m
Total assets€36.8m€38.0m€39.0m€39.7m€41.5m€44.1m€44.0m€49.5m
Cash and short-term investments€7.8m€7.3m€9.1m€25.8m€20.6m€29.3m€29.3m€31.3m
Debt———€1—€1—€1
Shareholders' equity€36.2m€37.3m€38.1m€39.0m€40.4m€42.8m€42.8m€47.4m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-50.5%-22.8%22.6%
Operating income—-15.0%—
Net income-18.9%—5.4%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-25.6%-24.0%12.7%10.4%
Net margin-43.4%-24.4%8.2%6.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-9.9-8.6-5.3-7.63.320.7-5.1-29.0-13.8-11.1
Price to sales4.23.87.90.70.62.15.03.15.23.3

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 16 Jun 2023.

FY2023FY2021
Paid in the year0.150.50

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.